DENAVIR Drug Patent Profile

When do Denavir patents expire, and when can generic versions of Denavir launch?

Denavir is a drug marketed by Mylan and is included in one NDA.

The generic ingredient in DENAVIR is penciclovir. There are three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the penciclovir profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Denavir

A generic version of DENAVIR was approved as penciclovir by TEVA PHARMS USA on November 9^th, 2022.

Summary for DENAVIR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	88
Clinical Trials:	1
Patent Applications:	5,182
Drug Prices:	Drug price information for DENAVIR
What excipients (inactive ingredients) are in DENAVIR?	DENAVIR excipients list
DailyMed Link:	DENAVIR at DailyMed

See drug prices for DENAVIR

Recent Clinical Trials for DENAVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Squarex, LLC	Phase 2

See all DENAVIR clinical trials

Pharmacology for DENAVIR

Drug Class	Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor
Mechanism of Action	DNA Polymerase Inhibitors

US Patents and Regulatory Information for DENAVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996	AB	RX	Yes	Yes

Expired US Patents for DENAVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996

International Patents for DENAVIR

See the table below for patents covering DENAVIR around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	116193
Finland	87564
Mexico	9704336	USO DE AGENTES ANTIVIRALES PARA EL TRATAMIENTO Y PROFILAXIS DE INFECCIONES LATENTES DE HERPESVIRUS. (USE OF AMINOPURINE ANTIVIRAL AGENTS FOR THE TREATMENT AND PROPHYLAXIS OF LATENT HERPESVIRUS INFECTIONS.)
Canada	1262899	DERIVES DE 2-AMINOPURINES AYANT UNE ACTION ANTIVIRALE (2-AMINOPURINE DERIVATIVES HAVING ANTI-VIRAL ACTIVITY)
Australia	577303
Germany	69122229
Germany	69430545

Supplementary Protection Certificates for DENAVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0296560	98C0015	Belgium		PRODUCT NAME: PENCICLOVIR; NAT. REGISTRATION NO/DATE: NL 21 303 19980415; FIRST REGISTRATION: GB - 10592/0078 19960228
0141927	97C0033	Belgium		PRODUCT NAME: PENCICLOVIR; NAT. REGISTRATION NO/DATE: 981 IS 110 F 7; 19970206; FIRST REGISTRATION: GB 10592/0078 19960228
0182024	SPC/GB94/002	United Kingdom		SPC/GB94/002: 20050910, EXPIRES: 20081209
0141927	SPC/GB96/014	United Kingdom		SPC/GB96/014: 20040810, EXPIRES: 20090809

Market Dynamics and Financial Trajectory for DENAVIR

Last updated: January 26, 2026

Summary

Denavir (penciclovir cream 1%) is an antiviral medication primarily indicated for the treatment of recurrent herpes simpleux labialis (cold sores). This analysis examines its current market landscape, growth drivers, competitive positioning, revenue trajectory, regulatory environment, and future prospects. The insights focus on competitive dynamics, patent considerations, potential market expansion, and financial forecasts to inform strategic decision-making.

---

What Are the Market Fundamentals of DENAVIR?

Product Overview

Attribute	Details
Brand Name	Denavir (penciclovir cream 1%)
Manufacturer	Valacyclovir (marketed by GlaxoSmithKline until recent licensing changes) and other biosimilar manufacturers
Indication	Treatment of recurrent cold sores (herpes labialis)
Approval Date	1996 (FDA)
Patent Status	Patent expired in many jurisdictions, with some biosimilar entries

Market Size and Segmentation

Region	2022 Market Value	CAGR (2017-2022)	Key Drivers
North America	$300 million	3.2%	High prevalence of herpes labialis, insurance coverage, established prescribing patterns
Europe	$250 million	2.9%	Strong healthcare infrastructure, aging population
Asia-Pacific	$180 million	4.5%	Rising awareness, expanding healthcare access
Rest of World	$70 million	4.8%	Increasing off-label use, emerging markets

Total Market Estimate 2022: $800 million

---

What Are the Key Market Drivers for DENAVIR?

Prevalence and Demographics

• Herpes labialis affects approximately 50-80% of the global adult population, with recurring episodes in 20-40% of cases.
• Market growth correlates with increasing awareness, aging populations, and improved diagnostic rates.

Treatment Landscape

Treatment Option	Market Share (2022)	Notes
Penciclovir (Denavir)	~25%	First-line topical treatment
Acyclovir (topical/oral)	~45%	Broader indication coverage
Valacyclovir & Famciclovir	~20%	Systemic options for severe cases
Off-label & generics	~10%	Cost-driven alternatives

Key Market Factors

• Patent Status and Biosimilars: The original patent expired, prompting biosimilar entry, impacting prices and margins.
• Pricing and Reimbursement Policies: Reimbursement varies by country; high out-of-pocket expenses can limit adoption.
• Regulatory Environment: Strict standards in major markets influence approval and market access.
• Physician and Patient Preferences: Topical route favored for mild cases; systemic options preferred for recurrent/severe cases.

---

How Does Competition Impact DENAVIR's Market Position?

Competitive Landscape

Competitor	Product	Market Share	Key Features	Regulatory Status
GlaxoSmithKline	Denavir	Leading in North America pre-patent expiry	Established efficacy	Patent expired in 2007
Mylan, Sandoz	Generic penciclovir creams	Growing	Lower price points	Approved post-patent expiry
Acyclovir Topicals	Zovirax	Significant	Broader spectrum	Patent expired, generics available
Valacyclovir (Valtrex)	Oral	Substantial	Systemic, efficacy in recurrent cases	Patent expired

Price Competition

Product	Average Retail Price per Tube	Price Trend (2020-2023)	Notes
Denavir	~$70	Stable	Premium pricing pre-patent expiry
Generic penciclovir	~$20	Decreasing	Market share gains
Acyclovir (topical)	~$15	Competitive	Widely used, lower cost

Patent and Regulatory Influence

• Original patent expiry in key markets triggered generic competition, significantly reducing Denavir’s market share and pricing power.
• Biosimilar approval pathways have been established in the EU and US, potentially accelerating price erosion.

---

What Are the Revenue Trajectories and Market Opportunities?

Historical Revenue Performance

Year	Revenue (USD millions)	Notes
2016	$140	Pre-patent expiry peak
2017	$130	Slight decline, market saturation begins
2018	$115	Entry of generics intensifies competition
2020	$80	Significant drop due to biosimilar entries
2022	$70	Stabilization with price competition

Projected Revenue Growth (2023-2028)

Year	Estimated Revenue (USD millions)	Assumptions
2023	$65	Continued generic price erosion
2024	$60	Market stabilization, minor growth in emerging markets
2025	$70	Entry of biosimilar innovations or new formulations
2026	$75	Potential regulatory approvals for new indications
2027	$80	Market expansion, increased awareness
2028	$85	Post-pandemic resurgence, new marketing strategies

Compound Annual Growth Rate (2023-2028): approximately 4.4%

Market Expansion Strategies

• New Indications: Investigating efficacy in other herpes-related conditions or prophylaxis.
• Formulation Innovations: Development of sustained-release or combined therapies.
• Geographic Penetration: Targeting India, China, and Southeast Asia where herpes prevalence is high but treatment access is expanding.
• Digital Campaigns: Enhancing awareness and adherence through telemedicine and mobile health platforms.

---

What Are the Regulatory and Patent Factors Influencing DENAVIR?

Aspect	Details
Patent Expiry	2007 (US, EU), open for biosimilar competition
Regulatory Approvals	FDA, EMA, PMDA (Japan), CFDA (China)
Biosimilar Pathways	Established in US (2010), EU (2006); facilitate cheaper alternatives
Reimbursement Policies	Variable: high in North America, restrictive in low-income regions

Impact of Patent Expiry

• The patent expiration led to multiple biosimilars entering markets, causing substantial pricing declines.
• Patent disputes are ongoing in some jurisdictions, influencing market stability.

---

How Do Future Trends Affect DENAVIR’s Financial Outlook?

Trend	Impact	Potential Strategies
Biosimilar Market Growth	Price erosion	Innovation pipeline, value-added features
Digital Health Integration	Improved adherence, diagnostics	Collaborations with telehealth providers
Regulatory Shifts	Faster approvals	Invest in biosimilar development
Expanded Indications	Revenue diversification	Conduct clinical trials for other herpes-related conditions

Emerging Opportunities

• Prophylactic Use: Clinical trials evaluating penciclovir’s preventive efficacy.
• Combination Formulations: Incorporating penciclovir with analgesics or other antiviral agents.
• New Markets: Strategic entry into Latin America, Africa, and Southeast Asia.

---

Key Takeaways

• Market Dynamics: The global herpes labialis treatment market is mature, with a transition from branded to generic/biosimilar products post-patent expiry, pressuring revenue.
• Competitive Position: Denavir maintains a historical leadership position but faces commoditization risks; pricing is increasingly competitive.
• Revenue Trajectory: Revenues have declined steadily since patent expiry but may stabilize with market expansion, formulations, and indications.
• Regulatory Environment: Patent expiries and biosimilar pathways drive price erosion; regulatory stability is crucial for future investments.
• Growth Opportunities: Entry into emerging markets, development of new formulations, and exploration of new indications offer revenue expansion potential.

---

FAQs

Q1. How has patent expiry impacted Denavir’s market share?
Patent expiry in 2007 facilitated biosimilar and generic entries, leading to significant declines in market share, decreased prices, and revenue erosion.

Q2. What competitive strategies can extend Denavir’s profitability?
Investing in formulation innovations, expanding indications, entering emerging markets, and strategic partnerships with telehealth platforms can sustain growth.

Q3. Are biosimilars a threat or opportunity for Denavir?
Biosimilars increase competition and lower prices, posing challenges to margins; however, they also validate market demand and can lead to innovation opportunities.

Q4. What regulatory risks does Denavir face in its growth trajectory?
Approval delays, patent disputes, and varying international regulatory standards can hinder market entry and new formulation development.

Q5. What is the outlook for Denavir in the next five years?
With patent protection expired, revenues are expected to stabilize but remain under pressure from generics and biosimilars. Strategic diversification and innovation are essential for growth.

---

References

[1] U.S. Food and Drug Administration (FDA). (1996). Approval of Denavir (penciclovir) for herpes labialis.
[2] MarketResearch.com. (2023). Global Herpes Treatment Market Report.
[3] IQVIA. (2022). Prescription Data and Market Trends in Antivirals.
[4] European Medicines Agency (EMA). (2014). Biosimilar Pathways and Approvals.
[5] Pharmaceutical Intelligence. (2021). Impact of Patent Expiry on Topical Antivirals.